Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | CCR5 | P51681 | 2/20 | 0.67 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580262 | 0.96 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5956482 | 0.93 | CCR5 (0.60) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13243455 | 0.92 | CHRM1 (0.67) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3004078 | 0.92 | CHRM1 (0.67) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8863400 | 0.91 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5386992 | 0.90 | CCR5 (0.69) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL16657347 | 0.88 | CCR5 (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5386538 | 0.88 | CCR5 (0.57) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5386502 | 0.88 | CCR5 (0.62) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL15575477 | 0.87 | CCR5 (0.54) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113637001-A | Synthesis method of droperidol intermediate | 安康市农业科学研究院 | 2021-11-12 | — | — | CN | claimed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022260016-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 学校法人近畿大学 | 2022-12-15 | — | — | WO | disclosed |
| EP-3976604-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2022-04-06 | — | — | EP | disclosed |
| CN-113924296-A | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2022-01-11 | — | — | CN | disclosed |
| CN-113637001-A | Synthesis method of droperidol intermediate | 安康市农业科学研究院 | 2021-11-12 | — | — | CN | disclosed |
| CN-113637001-A | Synthesis method of droperidol intermediate | 安康市农业科学研究院 | 2021-11-12 | — | — | CN | disclosed |
| EP-0812196-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0812196-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0755392-A4 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0755392-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996025934-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-29 | — | — | WO | disclosed |
| WO-1995028397-A1 | ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995007294-A1 | PSEUDO- AND NON-PEPTIDE BRADYKININ RECEPTOR ANTAGONISTS | SCIOS NOVA INC. (US) | 1995-03-16 | — | — | WO | disclosed |
| US-4446141-A | Hypotensive piperidine derivatives | KYOWA HAKKO KOGYO CO. (JP) | 1984-05-01 | — | — | US | disclosed |
| EP-0018417-B1 | NOVEL PIPERIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KYOWA HAKKO KOGYO CO., LTD (JP) | 1982-06-30 | — | — | EP | disclosed |
| EP-0018417-A1 | Novel piperidine derivatives and pharmaceutical compositions containing them | KYOWA HAKKO KOGYO CO., LTD (JP) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092890-A1 | 1, 3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC6, HDAC1, HDAC2 | CHRM1 3242/4885CHRM2 3674/4885CHRM4 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.